Substituted piperidine compounds and methods of their use

Details Substituted piperidine compounds and methods of their use Substituted piperidine compounds and methods of their use

2006-01-31

2006-01-31

Chang, Celia (Department: 1625)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Having -c-, wherein x is chalcogen, bonded directly to...

C514S331000, C546S192000, C546S236000, C546S237000, C546S238000, C546S239000, C546S240000

Reexamination Certificate

active

06992090

ABSTRACT:
Novel 3,4-disubstituted-4-aryl-piperidine compounds are disclosed. Pharmaceutical compositions containing the 3,4-disubstituted-4-aryl-piperidine compounds and methods of their pharmaceutical uses are also disclosed. The compounds disclosed are useful, inter alia, as antagonists of opioid receptors.

REFERENCES:
patent: 4115400 (1978-09-01), Zimmerman
patent: 4176186 (1979-11-01), Goldberg et al.
patent: 4891379 (1990-01-01), Zimmerman et al.
patent: 4987126 (1991-01-01), Bargiotti et al.
patent: 5159081 (1992-10-01), Cantrell et al.
patent: 5250542 (1993-10-01), Cantrell et al.
patent: 5270328 (1993-12-01), Cantrell et al.
patent: 5434171 (1995-07-01), Frank et al.
patent: 5972954 (1999-10-01), Foss et al.
patent: WO 02/30896 (2002-04-01), None
Cantrell et al. “Preparation of 4-phenyl . . . ” Ca 118:124401 (1993).
Cantrell et al. “Preparation of phenylpiperidine . . . ” Ca 119:139:107(1993).
Zimmerman et al. Discovery of a . . . CA 121:57300 (1994).
Frank et al. “Preparation of 3,4,4,-trisubstituted . . . ” CA 123:313767 (1995).
Werner et al. “Synthesis of trans-3,4-dimethyl . . . ” CA 124:87442 (1996).
Farrar et al. “Methods using a peripheral . . . ”CA 135:29144 (2001).
Carpenter “Methods using peripheral . . . ” CA 135:29160 (2001).
Smits “Antagonism by naloxone of . . . ” CA 86:83715 (1977).
Bagnol, D., et al., “Cellular localization and distribution of the cloned MU and KAPPA opioid receptors in rat gastrointestinal tract,”Neuroscience,1997, 81(2), 579-591.
Bagnol, D., et al., “Changes in enkephalin immunoreactivity of sympathetic ganglia and digestive tract of the cat after splanchnic nerve ligation,”Regul. Pept.,1993, 47, 259-273.
Bhargava, H.N., et al., “Effect of nitric oxide synthase inhibition on tolerance to the analgesic action of D-Pen2, D-Pen5enkephalin and morphine in the mouse,”Neuropeptides,1996, 30(3), 219-223.
Bilsky, E.J., et al., “Effects of naloxone and D-Phe-Cys-Tyr-D-Trp-Arg-Thr-Pen-Thr-NH2and the protein kinase inhibitors H7 and H8 on acute morphine dependence and antinociceptive tolerance in mice,”J. Pharmacol.&Exp. Ther.,1996, 277(1), 484-490.
Bryan, W.M., et al., “Combinatorial chemistry. Preparation of phenoxypropanolamines,”Tetrahed. Let.,2000, 41. 6997-7000.
Burkett, B.A., et al., “N-Fmoc-dehydroalanine: a versatile molecular scaffold for the rapid solid-phase synthesis of cycloaliphatic amino acids,”Tetrahed. Let.,2000, 41, 6661-6664.
Combs, A.P., et al., “N-Arylation of primary and secondary aliphatic amines on solid supports,”J. Comb. Chem.,2002, 4, 179-182.
DeHaven, R.N., et al., “Characterization of opioid receptors,”Curr. Port. In Pharmac.,Enna, S.J., et al. (Eds.), John Wiley & Sons, Inc., 1.4.1-1.4.12.
Dorland's Illustrated Medical Dictionary,27thEd.,W.B. Saunders Co.,1988, p. 816.
Dorland's Illustrated Medical Dictionary,27thEd.,W.B. Saunders Co.,1988, p. 375.
Dourish, C.T., et al., “Enhancement of morphine analgesia and prevention of morphine tolerance in the rat by the cholecystokinin antagonist L-364,718,”Eur. J. of Pharmacol.,1988, 147, 469-472.
Greene, T.W., et al.,Protective Groups in Organic Synthesis,2ndEd.,John Wiley&Sons, Inc.,1991.
Greene, T.W., et al.,Protective Groups in Organic Synthesis,3rdEd.,John Wiley&Sons, Inc., 1999.
Koch, T.R., et al., “Inhibitory neuropeptides and intrinsic inhibitory innervation of descending human colon,”Digestive Diseases&Sciences,1991, 36(6), 712-718.
Kreek, M.J., et al., “Naloxone, a specific opioid antagonist, reverses chronic idiopathic constipation,”The Lancet,1983, 261-262.
Livingston, E.H., et al., “Postoperative ileus,”Digestive Diseases and Sciences,1990, 35(1), 121-132.
Mack, D.J., “Paralytic ileus: response to naloxone,”Br. J. Surg.,1989, 76(10), p. 1101.
Mao, M.J., et al., “Oral administration of dextromethorphan prevents the development of morphine tolerance and dependence in rats,”Pain,1996, 67, 361-368.
Matthews, J., et al., “Based-promoted solid-phase synthesis of substituted hydantoins and thiohydantoins,”J. Org. Chem.,1997, 62, 6090-6092.
Mitch, C.H., et al., “Synthesis and absolute configuration of LY255582, a potent opioid antagonist,”J. of Org. Chem.,1991, 56, 1660-1663.
Nichols, M.L., et al., “Enhancement of the antiallodynic and antinociceptive efficacy of spinal morphine by antisera to dynorphin A (1-13) or MK-801 in a nerve-ligation model of peripheral neuropathy,”Pain,1997, 69, 317-322.
Orchin, et al.,The Vocabulary of Organic Chemistry, John Wiley&Sons, Inc.,1980, 126.
Physicians' Desk Reference,1999.
Piscopio, A.D., et al., “A second generation solid phase approach to Freidinger lactams: application of Fukuyama's amine synthesis and cyclative release via ring closing metathesis,”Tetrahed. Let.,1998, 39, 2667-2670.
Piscopio, A.D., et al., “Ring closing metathesis in organic synthesis: Evolution of a high speed, solid phase method for the preparation of β-turn mimetics,”Tetrahedron,1999, 55, 8189-8198.
Raynor, K., et al., “Pharmacological characterization of the cloned κ-,δ-, and μ-opioid receptors,”Mol. Pharmacol.,1994, 45, 330-334.
Reisine, T., et al., “Opioid analgesics and antagonists,”Goodman&Gilman's The Pharmacological Basis of Therapeutics,9thEd., 1996, 521-555.
Remington's Sciences, Mack. Pub. Co.,1980.
Resnick, J., et al., “Delayed gastric emptying and postoperative ileus after nongastric abdominal surgery: Part I,”Am. J. of Gastroenterology,1997, 92(5), 751-762.
Resnick, J., et al., “Delayed gastric emptying and postoperative ileus after nongastric abdominal surgery: Part II,”Am. J. of Gastroenterology,1997, 92(6), 934-940.
Schang, J.C., et al., “Beneficial effects of naloxone in a patient with intestinal pseudoobstruction,”Am. J. Gastroenterology,1985, 80(6), 407-411.
Schuller, A.G.P., et al., “M6G, but not morphine, inhibits GI transit in MU opioid receptor deficient mice,”Soc. For Neuroscience,1998, 24, 210.7, p. 524 (abstract).
Werner, J.A., et al., “Synthesis of trans-3,4-dimethyl-4-(3-hydroxyphenyl)piperidine opioid antagonists: application of the cis-thermal elimination of carbonates to alkaloid synthesis,”J. Org. Chem.,1996, 61, 587-597.
Wittert, G., et al., “Tissue distribution of opioid receptor gene expression in the rat,”Biochem.&Biophys. Res. Commun.,1996, 218, 877-881.
Yang, L., et al., “Solid phase synthesis of Fmoc N-methyl amino acids: application of the Fukuyama amine synthesis,”Tetrahed. Let.,1997, 38(42), 7307-7310.

Affiliated with

Also associated with

Rating

Substituted piperidine compounds and methods of their use does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Substituted piperidine compounds and methods of their use, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Substituted piperidine compounds and methods of their use will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3597915